MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference
MeiraGTx Holdings (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will present at the virtual Chardan 5th Annual Genetic Medicines Conference on October 5, 2021, at 10:30 a.m. ET. Additionally, Dr. Forbes will participate in a panel titled “The Next Big Thing in Vector Gene Therapy—Non-traditional Vectors and Gene Regulation” at 9:30 a.m. ET on the same day.
A live webcast of the presentation will be available on the company's investor page for 30 days.
MeiraGTx is focused on gene therapy for inherited retinal diseases, neurodegenerative diseases, and xerostomia.
- None.
- None.
LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the virtual Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 10:30 a.m. ET.
Dr. Forbes will also participate on a panel discussion titled “The Next Big Thing in Vector Gene Therapy—Non-traditional Vectors and Gene Regulation” taking place on Tuesday, October 5, 2021 at 9:30 a.m. ET.
A live webcast of the company presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for approximately 30 days following the presentation.
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
For more information, please visit www.meiragtx.com.
Contacts
Investors:
MeiraGTx
Investors@meiragtx.com
or
Media:
Real Chemistry
Ben Rickles
(404) 502-6766
brickles@realchemistry.com
FAQ
When is MeiraGTx's presentation at the Chardan Conference?
What is the topic of the panel discussion at the conference featuring MeiraGTx?
Where can I watch MeiraGTx's conference presentation?
How long will the webcast of MeiraGTx's presentation be available?
What therapeutic areas does MeiraGTx focus on?
